DOP34 Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel Disease

Li, Y.(1)*;Yu, Z.(1);Schenk, M.(1);Lagovsky, I.(2);Illig, D.(1);Walz, C.(3);Rohlfs, M.(1);Conca, R.(1);Muise, A.(4);Snapper, S.(5);Uhlig, H.(6);Garty, B.(7);Klein, C.(1);Kotlarz, D.(1);

(1)Dr. von Hauner Children’s Hospital- Ludwig-Maximilians-Universität LMU, Department of Pediatrics, Munich, Germany;(2)Rabin Medical Center and Sackler School of Medicine, Felsenstein Medical Research Center, Tel Aviv, Israel;(3)Faculty of Medicine- LMU Munich, Institute of Pathology, Munich, Germany;(4)Hospital for Sick Children, SickKids Inflammatory Bowel Disease Center, Toronto, Canada;(5)Boston Children’s Hospital, Division of Gastroenterology- Hepatology and Nutrition, Boston, United States;(6)University of Oxford, Translational Gastroenterology Unit and Department of Pediatrics- and Biomedical Research Centre, Oxford, United Kingdom;(7)Tel Aviv University, Sackler School of Medicine, Tel-Aviv, Israel;

Background

Pattern recognition receptors (PRRs) serve as a hub of immune responses to microbes in the gut and play a critical role in maintaining intestinal homeostasis. Toll-like receptor 4 (TLR4) represents an important PRR that can recognize the gram-negative bacterial cell wall component lipopolysaccharide (LPS). Upon binding to LPS, TLR4 forms a multimeric complex with the indispensable co-receptor myeloid differentiation protein 2 (MD2) facilitating selection of TLR4 as cargo for endocytosis and TLR4-mediated activation of downstream signalling. Despite the critical role of TLR4 in innate immunity, no patients with TLR4 or MD2 deficiency have yet been reported.

Methods

To investigate potential genetic causes for two related patients presenting with very early onset Inflammatory Bowel Disease (VEO-IBD) and/or pneumonia, we have performed whole exome sequencing (WES). To assess the functional consequences of the identified LY96 (encoding for MD2) variant, we generated a CRISPR/Cas9-mediated knockout (KO) of MD2 or knockin (KI) of the patient mutation in induced pluripotent stem cells (iPSCs) and studied TLR4-mediated signalling, cytokine responses, and bacterial handling in iPSC-derived macrophages.

Results

Genetic analysis identified a 3 bp homozygous in-frame deletion in the LY96 gene (NM_015364.5, c.347_349delCAA; p.Thr116del) in our index patients following an autosomal recessive inheritance pattern. Immunoblotting revealed an altered protein expression of overexpressed Flag-tagged mutant MD2 protein due to impaired N-linked glycosylation. Correspondingly, iPSC-derived MD2-deficient macrophages showed an impaired LPS-induced TLR4 endocytosis. As a functional consequence, we could detect reduced NF-κB and MAPK signalling (phosphorylation of NF-κB p65 subunit, ERK1/2, and p38 MAPK) and dysregulated inflammasome activation (IL-1b production and secretion) upon challenge with LPS. Gentamycin protection assays and live cell imaging suggested that MD2-deficient macrophages exhibit an impaired phagocytosis of microbial pathogens. In addition, macrophages with mutant MD2 showed decreased cytokine expression (e.g., IFNB, IL6, IL10, and TNF) in response to LPS or gram-negative bacteria (E. coli and Salmonella typhimurium) but not gram-positive bacteria (Listeria monocytogenes).

Conclusion

Human MD2 deficiency is an inborn error of immunity that may predispose to VEO-IBD associated with altered TLR4-mediated signalling, cytokine responses, and bacterial handling. The first description of patients with MD2 deficiency provides critical insights on human TLR4/MD2 biology and warrants caution on therapeutics strategies targeting TLR4 signalling.